Axsome Therapeutics (NASDAQ:AXSM) Director Mark Coleman Sells 25,000 Shares of Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Mark Coleman sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $161.11, for a total value of $4,027,750.00. Following the completion of the sale, the director owned 47,140 shares in the company, valued at $7,594,725.40. The trade was a 34.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Axsome Therapeutics Stock Up 0.4%

Shares of NASDAQ AXSM opened at $163.89 on Friday. The company’s 50 day moving average price is $175.78 and its 200-day moving average price is $146.07. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.50 and a current ratio of 1.55. Axsome Therapeutics, Inc. has a 52-week low of $86.99 and a 52-week high of $191.50. The company has a market capitalization of $8.38 billion, a P/E ratio of -44.41 and a beta of 0.40.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Monday, February 23rd. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.14. The business had revenue of $196.00 million during the quarter, compared to the consensus estimate of $191.33 million. Axsome Therapeutics had a negative net margin of 28.69% and a negative return on equity of 232.61%. The company’s quarterly revenue was up 65.0% compared to the same quarter last year. Equities analysts forecast that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on AXSM. Wells Fargo & Company lifted their target price on Axsome Therapeutics from $193.00 to $202.00 and gave the stock an “overweight” rating in a report on Tuesday. Mizuho set a $230.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, February 19th. Royal Bank Of Canada lifted their price objective on shares of Axsome Therapeutics from $219.00 to $222.00 and gave the company an “outperform” rating in a research note on Tuesday. Robert W. Baird set a $209.00 target price on shares of Axsome Therapeutics in a research note on Tuesday, January 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a research note on Wednesday, January 21st. Seventeen analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $216.12.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Axsome Therapeutics by 6.0% during the 3rd quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock worth $507,739,000 after purchasing an additional 235,626 shares in the last quarter. Stanley Laman Group Ltd. bought a new position in shares of Axsome Therapeutics in the third quarter valued at approximately $2,125,000. Aberdeen Group plc boosted its position in shares of Axsome Therapeutics by 15.5% during the third quarter. Aberdeen Group plc now owns 94,648 shares of the company’s stock valued at $11,495,000 after buying an additional 12,732 shares during the last quarter. Swiss National Bank grew its holdings in Axsome Therapeutics by 6.9% during the second quarter. Swiss National Bank now owns 65,200 shares of the company’s stock worth $6,806,000 after buying an additional 4,200 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in Axsome Therapeutics by 55.4% during the second quarter. Bank of New York Mellon Corp now owns 203,632 shares of the company’s stock worth $21,257,000 after buying an additional 72,609 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Key Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $260 price target and forecasts a large rebound into FY‑2027 (FY‑2027 EPS of $11.87 with strong quarterly ramps). This upbeat long‑term view supports investor optimism. Read More.
• Positive Sentiment: Recent company results showed a Q4 EPS beat and revenue up ~65% year‑over‑year, which provides fundamental support for the stock despite near‑term model revisions. Read More.
• Neutral Sentiment: Reported short interest data in late February shows effectively zero shares short (the published figures contain anomalies/NaN), so short‑position dynamics appear minimal and unlikely to be a near‑term driver. Read More.
• Negative Sentiment: HC Wainwright trimmed multiple near‑term 2026 estimates (Q1‑Q3 and FY‑2026 materially lowered; Q4‑2026 also revised down from prior forecasts). These cuts signal more modest near‑term profitability than previously expected and increase uncertainty for 2026 results. Read More.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.